• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Humanized Chimeric Antigen Receptor (CAR) T cells.

作者信息

Kozani Pouya Safarzadeh, Kozani Pooria Safarzadeh, O'Connor Roddy S

机构信息

Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, P.O. Box 41446/66949, Iran.

Student Research Committee, Medical Biotechnology Research Center, School of Nursing, Midwifery, and Paramedicine, Guilan University of Medical Sciences, Rasht, P.O. Box 41446/66949, Iran.

出版信息

J Cancer Immunol (Wilmington). 2021;3(4):183-187.

PMID:35128536
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8813057/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9fb/8813057/8e896c719767/nihms-1768907-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9fb/8813057/8e896c719767/nihms-1768907-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9fb/8813057/8e896c719767/nihms-1768907-f0001.jpg

相似文献

1
Humanized Chimeric Antigen Receptor (CAR) T cells.人源化嵌合抗原受体（CAR）T细胞。
J Cancer Immunol (Wilmington). 2021;3(4):183-187.
2
Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells.人源化抗CD30嵌合抗原受体T细胞对霍奇金淋巴瘤细胞显示出强大的临床前活性。
Front Cell Dev Biol. 2022 Jan 12;9:775599. doi: 10.3389/fcell.2021.775599. eCollection 2021.
3
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma.新型CD37、人源化CD37和双特异性人源化CD37-CD19嵌合抗原受体T细胞特异性靶向淋巴瘤。
Cancers (Basel). 2021 Feb 26;13(5):981. doi: 10.3390/cancers13050981.
4
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].[两例在鼠源BCMA CAR-T细胞治疗后进展的难治性多发性骨髓瘤患者的人源化BCMA CAR-T细胞挽救治疗]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):502-507. doi: 10.3760/cma.j.issn.0253-2727.2021.06.010.
5
Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy.人源化CD19嵌合抗原受体T细胞（CAR-T）作为鼠源CD19 CAR-T细胞治疗后复发的B淋巴细胞白血病中枢神经系统白血病（CNSL）挽救治疗的疗效和安全性
Oncol Lett. 2021 Nov;22(5):788. doi: 10.3892/ol.2021.13049. Epub 2021 Sep 16.
6
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
7
Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma.嵌合抗原受体修饰 T 细胞疗法治疗血小板衍生生长因子受体 α 阳性横纹肌肉瘤。
Cancer. 2020 May 1;126 Suppl 9:2093-2100. doi: 10.1002/cncr.32764.
8
[Activity comparison of humanized CD19 CAR-T cells with murine CD19 CAR-T on Nalm-6 cells and xenograft tumor model].[人源化CD19嵌合抗原受体T细胞与鼠源CD19嵌合抗原受体T细胞在Nalm-6细胞和异种移植肿瘤模型上的活性比较]
Zhonghua Zhong Liu Za Zhi. 2021 Aug 23;43(8):827-832. doi: 10.3760/cma.j.cn112152-20190622-00392.
9
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.在复发/难治性急性淋巴细胞白血病患者中，人源化 CD19 靶向嵌合抗原受体 T（CAR-T）细胞具有强大的抗白血病活性。
Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28.
10
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.CD47嵌合抗原受体T细胞（CD47-CAR-T细胞）可有效杀伤靶癌细胞并抑制胰腺肿瘤生长。
Cancers (Basel). 2017 Oct 21;9(10):139. doi: 10.3390/cancers9100139.

引用本文的文献

1
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.嵌合抗原受体（CAR）-T细胞疗法抗原依赖性耐药机制。
Cancer Cell Int. 2025 Feb 24;25(1):64. doi: 10.1186/s12935-025-03697-y.
2
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells.抗原识别结构域的人源化不影响基于人源化纳米抗体的 CD19 重定向 CAR-T 细胞的抗原结合、细胞因子分泌和抗肿瘤反应性。
J Transl Med. 2024 Jul 25;22(1):679. doi: 10.1186/s12967-024-05461-8.
3
Universal CAR 2.0 to overcome current limitations in CAR therapy.

本文引用的文献

1
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.优化嵌合抗原受体 T 细胞疗法在 B 细胞急性淋巴细胞白血病中的临床疗效：回顾过去，展望未来。
Front Immunol. 2021 Oct 28;12:765097. doi: 10.3389/fimmu.2021.765097. eCollection 2021.
2
CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production.嵌合抗原受体 T 细胞（CAR T-cells）依赖于烟酰胺腺嘌呤二核苷酸（NADH）氧化与三磷酸腺苷（ATP）生成的偶联。
Cells. 2021 Sep 6;10(9):2334. doi: 10.3390/cells10092334.
3
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
通用 CAR 2.0 克服 CAR 疗法当前的局限性。
Front Immunol. 2024 Jun 19;15:1383894. doi: 10.3389/fimmu.2024.1383894. eCollection 2024.
4
CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.嵌合抗原受体 T 细胞免疫疗法治疗卵巢癌：让沉默的杀手安静下来。
Front Immunol. 2023 Dec 7;14:1302307. doi: 10.3389/fimmu.2023.1302307. eCollection 2023.
5
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.嵌合抗原受体（CAR）T细胞疗法中的位点特异性转基因整合
Biomark Res. 2023 Jul 4;11(1):67. doi: 10.1186/s40364-023-00509-1.
6
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.经新型 VHH 基嵌合抗原受体修饰的 T 细胞对 CD19 表现出与 FMC63 基嵌合抗原受体相当的肿瘤杀伤效力。
Front Immunol. 2023 Feb 16;14:1063838. doi: 10.3389/fimmu.2023.1063838. eCollection 2023.
7
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma.人源化与鼠源化 CD19 和 CD22 CAR-T 细胞鸡尾酒疗法治疗难治/复发 B 细胞淋巴瘤的安全性和有效性。
Cells. 2022 Dec 16;11(24):4085. doi: 10.3390/cells11244085.
8
Nanobody-based CAR-T cells for cancer immunotherapy.用于癌症免疫治疗的基于纳米抗体的嵌合抗原受体T细胞。
Biomark Res. 2022 Apr 25;10(1):24. doi: 10.1186/s40364-022-00371-7.
比较 TCR 和 CAR 信号转导，为具有优异抗原敏感性和体内功能的 CAR 设计提供信息。
Sci Signal. 2021 Aug 24;14(697):eabe2606. doi: 10.1126/scisignal.abe2606.
4
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.人源化 CD19 靶向嵌合抗原受体（CAR）T 细胞在初治和 CAR 暴露的儿童和青年复发性或难治性急性淋巴细胞白血病中的应用。
J Clin Oncol. 2021 Sep 20;39(27):3044-3055. doi: 10.1200/JCO.20.03458. Epub 2021 Jun 22.
5
In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.《似羊羔温顺；如雄狮勇猛：嵌合抗原受体 T 细胞增强急性淋巴细胞白血病疗效之路》
Mol Cancer Ther. 2021 Jul;20(7):1223-1233. doi: 10.1158/1535-7163.MCT-20-1089. Epub 2021 Apr 26.
6
Strategies for Dodging the Obstacles in CAR T Cell Therapy.规避CAR-T细胞疗法中障碍的策略
Front Oncol. 2021 Apr 1;11:627549. doi: 10.3389/fonc.2021.627549. eCollection 2021.
7
Novel antigens of CAR T cell therapy: New roads; old destination.嵌合抗原受体T细胞疗法的新型抗原：新途径；旧目标。
Transl Oncol. 2021 Jul;14(7):101079. doi: 10.1016/j.tranon.2021.101079. Epub 2021 Apr 13.
8
A novel full-human CD22-CAR T cell therapy with potent activity against CD22 B-ALL.一种新型的全人源CD22嵌合抗原受体T细胞疗法，对CD22阳性B细胞急性淋巴细胞白血病具有强大活性。
Blood Cancer J. 2021 Apr 10;11(4):71. doi: 10.1038/s41408-021-00465-9.
9
FDA approves first BCMA-targeted CAR-T cell therapy.美国食品药品监督管理局批准首款靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法。
Nat Rev Drug Discov. 2021 May;20(5):332. doi: 10.1038/d41573-021-00063-1.
10
Immunogenicity of CAR T cells in cancer therapy.嵌合抗原受体 T 细胞在癌症治疗中的免疫原性。
Nat Rev Clin Oncol. 2021 Jun;18(6):379-393. doi: 10.1038/s41571-021-00476-2. Epub 2021 Feb 25.